ArticleCureus2025
Evaluation of Paediatric Melanoma Management in a UK Major Tertiary Centre: A Twenty-Year Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study evaluates the management of paediatric melanoma at a tertiary centre, comparing clinical practices with international guidelines from the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT) and the National Comprehensive Cancer Network (NCCN) to highlight real-world practices and make recommendations for future research priorities. The differences between conventional and Spitzoid melanomas were also explored in a subgroup analysis.
backgroundPaediatric melanoma is rare and is most commonly caused by UV exposure or familial mutations. Management of paediatric melanoma is challenging due to diagnostic, histological and treatment complexities, coupled with limited paediatric-specific evidence. Treatment typically involves wide local excision (WLE) for localised melanoma. Advanced cases may require systemic therapy, such as chemotherapy or immunotherapy; however, paediatric-specific clinical trials to support treatment protocols are limited, and therefore, treatment is initiated on a case-by-case basis.
methodsA retrospective case series analysis was completed for all melanoma patients aged between 0 and 15 years presenting at Birmingham Children's Hospital, a UK tertiary paediatric centre, between 2003 and 2023. Statistical analysis was performed using the t-test for continuous variables and Fisher's exact test for categorical data.
resultsEight cases were treated, with an average diagnosis age of 9.8 years. Tumours were most often located on the extremities (4/8, 50%), followed by the head and neck (2/8, 25%). All cases underwent WLE, and three (3/8, 38%) were considered for sentinel lymph node biopsy (SLNB). There was 100% (8/8) compliance with discussion in a specialist melanoma multidisciplinary team (MDT) and review by experienced dermatopathologists. Follow-up imaging and compliance with guidelines were inconsistent, with only two (2/8, 25%) receiving recommended imaging.
conclusionsFindings show excellent compliance with key recommendations that all cases should be discussed in a specialist melanoma MDT and histology reviewed by an experienced dermatopathologist. There was variability in biopsy techniques, imaging, and follow-up, suggesting a need for standardised guidelines to guide best practice. Future research should include multicentre, randomised, blinded paediatric-specific clinical trials to compare outcomes to potential treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.